Diligence memo · auto-generated · as of July 2, 2026
Oric Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Oric Pharmaceuticals, Inc. operates in Biotechnology, based in SOUTH SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Oric Pharmaceuticals, Inc. has raised $335M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $125M on 2024-01-23.
Most recent recorded round closed around 2025-05-29.
Valuation (modeled)modeled
Provath models Oric Pharmaceuticals, Inc. at approximately $1.0B (range $567M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.15× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era. Within the normal band (115% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 13 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 90% of those peers.
Closest niche peers: Kriya Therapeutics, Inc., Pathos AI, Inc., Sensei Biotherapeutics, Inc., Odyssey Therapeutics, Inc., Rhodenergy An Environmental Co Corp.
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.